https://charts.traderzeitung.de/phases/CA29286X1015 string(1425) "{"isin":"CA29286X1015","name":"enGene Therapeutics Inc","stock_id_xnas":132475449,"stock_id_xnys":132475450,"generated_at":"2026-09-24 01:36:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":1.9,"close_at":"2026-09-21 15:28:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.965,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":3.4211},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":2.06,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":4.8346},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":2.005,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-2.6699},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

enGene Therapeutics Aktie News & Nachrichten

[WKN: A425M8 | Symbol: ENGN]

Realtimekurs

enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über enGene Therapeutics gefunden werden.

enGene Therapeutics Nachrichtenticker öffnen

MT Newswires 18.06.2026 21:33 Uhr

enGene Therapeutics Aktie News & Nachrichten

Artikel aus der Redaktion der Trader-Zeitung

Sektor-Update: Gesundheitsaktien fallen am späten Nachmittag

EnGene-Aktien fallen nach Herabstufung durch Morgan Stanley

enGenes Detalimogene-Haltbarkeitsprofil 'nicht wettbewerbsfähig', sagt Morgan Stanley

Morgan Stanley stuft enGene von "Equalweight" auf "Underweight" herab